• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

Artax Biopharma

Monday, June 03, 2024
CP
Immunology
Artax Biopharma is a clinical-stage biotechnology company transforming the treatment of T Cell-driven autoimmune diseases. Our first-in-class oral small molecules aim to deliver immune system modulation without immunosuppression, potentially unlocking new treatment options. Our lead program AX-158 will deliver results in a Phase 2a Proof of Concept study in psoriasis later in 2024. In contrast to agents targeting individual cytokines, we believe our approach will allow us to address a broad spectrum of patients. By having the potential to impact multiple cytokines, we hope to address areas of high unmet need beyond where targeted therapies have achieved success.
Artax Biopharma
Company Website: https://artaxbiopharma.com/
Lead Product in Development: AX-158

Company HQ City

Cambridge

Company HQ State

Massachusetts

Company HQ Country

United States

CEO/Top Company Official

Robert Armstrong, PhD

Development Phase of Primary Product

Phase II
Back to Session List

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS